Acetylcysteine

證據等級: L5

預測適應症: 10 個

Acetylcysteine: From Mucolytic/Acetaminophen Antidote to Thrombotic Disease

One-Sentence Summary

Acetylcysteine (NAC) is a well-established mucolytic agent and antioxidant with proven efficacy in acetaminophen overdose, cystic fibrosis, and chronic obstructive pulmonary disease. The TxGNN model predicts it may be effective for Thrombotic Disease, with 9 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Mucolytic agent; antidote for acetaminophen overdose (well-established globally; no Singapore registration on record)
Predicted New Indication	Thrombotic Disease
TxGNN Prediction Score	99.96%
Evidence Level	L1
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the regulatory dataset. Based on known published information, Acetylcysteine (NAC) is a small-molecule thiol compound that functions primarily as a glutathione (GSH) precursor and direct antioxidant. Its best-characterized clinical roles include mucolysis — achieved by cleaving disulfide bonds within mucin polymers — and hepatoprotection via GSH replenishment following acetaminophen overdose.

The mechanistic link to thrombotic disease is substantiated in peer-reviewed literature: NAC cleaves disulfide bonds within ultra-large von Willebrand factor (ULVWF) multimers, reducing their size and platelet-binding capacity, thereby inhibiting pathological platelet aggregation and microthrombosis. This mechanism has been validated in mouse and baboon models of thrombotic thrombocytopenic purpura (TTP) (PMID 28011677) and mechanistically characterized in human plasma (PMID 21266777). Simultaneously, NAC's antioxidant activity — via GSH replenishment — attenuates endothelial oxidative damage, a key driver of thrombotic microangiopathy.

The primary clinical application with the strongest evidence focuses on Transplantation-Associated Thrombotic Microangiopathy (TA-TMA), a severe subtype of thrombotic disease occurring post-HSCT. A completed Phase 3 trial (NCT03252925, n=170) has directly evaluated NAC's safety and efficacy in TA-TMA, and a 2022 RCT (PMID 35940529) further supports prophylactic use. TA-TMA and acquired TTP share overlapping pathophysiology involving ADAMTS13 dysfunction and ULVWF accumulation, making this mechanistic extrapolation scientifically sound. Caution is warranted, however, when extrapolating the broad label "thrombotic disease" to other subtypes (e.g., arterial thrombosis, deep vein thrombosis), which remain unsupported by direct clinical evidence at this time.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03252925	Phase 3	Completed	170	Prospective trial evaluating safety and efficacy of NAC in transplant-associated thrombotic microangiopathy (TA-TMA); the highest-grade direct clinical evidence for this indication and primary basis for L1 classification
NCT05907486	Phase 3	Unknown	260	NAC for prevention of thrombotic events after allogeneic HSCT; largest enrollment in this indication — completion will substantially reinforce the L1 evidence base
NCT07279610	Phase 2/3	Active, Not Recruiting	44	Multicenter prospective single-arm trial assessing NAC efficacy and safety for TA-TMA; ongoing companion to NCT03252925
NCT03636932	Phase 2	Completed	40	RENACTIF: Randomized double-blind placebo-controlled crossover trial (chronic kidney disease patients) evaluating NAC's effect on thrombotic phenotype through oxidative stress reduction
NCT03460808	Phase 1/2	Unknown	200	Atorvastatin + NAC + Danazol vs. Danazol monotherapy in steroid-resistant/relapsed immune thrombocytopenia (ITP); mechanistically related to thrombotic disease, but NAC's independent contribution cannot be isolated
NCT04368598	Phase 2	Unknown	44	NAC + high-dose dexamethasone in newly diagnosed primary ITP; ITP involves platelet-related pathology with indirect relevance to thrombotic disease mechanisms
NCT01808521	Early Phase 1	Completed	3	Pilot study of IV NAC in suspected TTP undergoing therapeutic plasma exchange; directly relevant indication, but very small sample — preliminary feasibility only
NCT06518044	Phase 2	Not Yet Recruiting	30	NAC to promote hematopoietic recovery after haploidentical transplantation in severe aplastic anemia; indirectly related — awaiting initiation
NCT05551624	Early Phase 1	Completed	15	Atorvastatin + NAC combination for platelet count elevation in steroid-resistant ITP; very small sample and combination design limit independent NAC evidence

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35940529	2022	RCT	Transplantation and Cellular Therapy	Open-label randomized placebo-controlled trial demonstrating NAC as effective prophylactic therapy for TA-TMA in HSCT; direct clinical validation
37311880	2023	Retrospective Cohort	Annals of Hematology	Cohort study examining association between NAC treatment and in-hospital mortality reduction in acquired TTP; supports benefit despite ongoing controversy
21266777	2011	Mechanistic Study	Journal of Clinical Investigation	NAC reduces size and activity of ULVWF multimers in human plasma and mice — the foundational mechanistic study underpinning NAC's use in TTP/TA-TMA
28011677	2017	Animal Study	Blood	NAC validated in mouse and baboon TTP models; demonstrates VWF cleavage via free thiols and prevention of platelet/VWF string propagation
32243196	2020	Review (Drug Repurposing)	Expert Review of Hematology	Summarizes repurposed drugs in immune-mediated TTP including NAC, rituximab, bortezomib, and caplacizumab; contextualizes NAC's place in evolving treatment landscape
33540569	2021	Review	Journal of Clinical Medicine	Comprehensive review of TTP pathophysiology, diagnosis, and management including ADAMTS13 deficiency and emerging therapies
28382967	2017	Review	Nature Reviews Disease Primers	Authoritative disease primer on TTP covering pathophysiology, clinical features, treatment, and relapse risk
28416507	2017	Review	Blood	TTP overview including ADAMTS13 deficiency mechanism, plasma exchange as mainstay, and current treatment landscape
28645643	2017	Review/Guideline	Transfusion Clinique et Biologique	TTP management including role of rituximab, refractory disease, and NAC as an emerging agent
32614622	2021	Review	Platelets	Novel antiplatelet strategies targeting VWF and GPIb in thrombotic microangiopathy; provides mechanistic context for NAC's ULVWF-targeting approach

Singapore Market Information

Acetylcysteine is currently not registered in Singapore. No product authorizations are on record with HSA. This means there is no locally approved labeling, approved indication text, or registered dosage form available for reference.

Clinicians wishing to use NAC in Singapore would need to rely on overseas approved labeling (e.g., US FDA, EMA) and comply with the Health Sciences Authority's frameworks for use of unregistered therapeutic products.

Safety Considerations

Please refer to the package insert for safety information.

No Singapore-specific warning or contraindication data is available. Detailed TFDA/HSA package insert data and drug-drug interaction data were not retrievable at the time of this report. These gaps are classified as Blocking for formal safety pre-screening and must be resolved before clinical application.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed Phase 3 trial (NCT03252925, n=170) directly supports NAC's safety and efficacy in transplant-associated thrombotic microangiopathy (TA-TMA), and a 2022 RCT (PMID 35940529) corroborates prophylactic benefit in the same population. A concurrent Phase 3 trial (NCT05907486, n=260) is underway, which upon completion will further consolidate L1-grade evidence. However, the clinical scope must be carefully bounded to TA-TMA and TTP subtypes where the mechanistic and clinical evidence is strongest — extrapolation to broader thrombotic disease categories is not yet supported.

To proceed, the following is needed:

Obtain full published results from NCT03252925 (Phase 3 TA-TMA, completed) to assess effect size, subgroup outcomes, and adverse event profile
Await completion and reporting of NCT05907486 (Phase 3, n=260) for confirmatory evidence
Narrow the clinical target: define whether the intended indication is TA-TMA, acquired TTP, or another thrombotic microangiopathy subtype to match available evidence
Resolve the Blocking data gap: retrieve and review the HSA/TFDA package insert (or international equivalents) for full warnings, contraindications, and drug interaction profile — especially relevant given post-transplant polypharmacy
Obtain detailed mechanism of action data from DrugBank to support regulatory and clinical rationale documentation
Define the intended route of administration (IV vs. oral) and confirm dosing regimen for the target indication, as NAC's PK profile differs significantly by route
Evaluate drug interaction risk specifically in HSCT patients receiving immunosuppressants (calcineurin inhibitors, mTOR inhibitors) where oxidative stress and renal function are critical variables
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.